Predictors of exacerbation frequency in chronic obstructive pulmonary disease

European Journal of Medical Research

Volumn 19, Issue 1, 2014, Pages

  Yang, Hui ^a,b   Xiang, Pingchao ^b   Zhang, Erming ^b   Guo, Wei'An ^b   Shi, Yanwei ^b   Zhang, Shuo ^b   Tong, Zhaohui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Comorbidity; Exacerbation; Forced expiratory volume; Positive pressure ventilation

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INVASIVE POSITIVE PRESSURE VENTILATION; POSITIVE END EXPIRATORY PRESSURE; PROSPECTIVE STUDY; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; CLASSIFICATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84899985569     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-19-18     Document Type: Article

References (24)

1. World Health Report Geneva: World Health Organization Available from URL: http://www.who.int/whr/2000/en/statistics.htm; 2000
2. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary updated 2009. GOLD Executive and Science Committees, http://www.gold-copd.org
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R, Am J Respir Crit Care Med 2013 187 347 365 10.1164/rccm.201204-0596PP 22878278
4. Impact of exacerbations on COPD. Anzueto A, Eur Respir Rev 2010 19 113 118 10.1183/09059180.00002610 20956179
5. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA, Thorax 2002 57 847 852 10.1136/thorax.57.10.847 12324669
6. Susceptibility to exacerbation in chronic obstructive pulmonary disease. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, N Engl J Med 2010 363 1128 1138 10.1056/NEJMoa0909883 20843247
7. Azithromycin for prevention of exacerbations of COPD. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR, N Engl J Med 2011 365 689 698 10.1056/NEJMoa1104623 21864166
8. COPD exacerbations 1: epidemiology. Donaldson GC, Wedzicha JA, Thorax 2006 61 164 168 10.1136/thx.2005.041806 16443707
9. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, N Engl J Med 2007 356 775 789 10.1056/NEJMoa063070 17314337
10. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, N Engl J Med 2008 359 1543 1554 10.1056/NEJMoa0805800 18836213
11. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Donaldson GC, Seemungal T, Jeffries DJ, Wedzicha JA, Eur Respir J 1999 13 844 849 10.1034/j.1399-3003.1999.13d25.x 10362051
12. COPD exacerbations: definitions and classifications. Burge S, Wedzicha JA, Eur Respir J Suppl 2003 41 46s 53s 12795331
13. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA, Am J Respir Crit Care Med 2009 179 369 374 10.1164/rccm.200807- 1067OC 19074596
14. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H, Eur Respir J 2003 21 74 81 10.1183/09031936.03.00031402 12570112
15. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. Calverley PMA, Pauwels R, Vestbo J, Jones PW, Pride N, Gulsvick A, Lancet 2003 361 449 10.1016/S0140-6736(03)12459-2 12583942
16. Predictive accuracy of patient-reported exacerbation frequency in COPD. Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA, Eur Respir J 2011 37 501 507 10.1183/09031936.00035909 20650988
17. Validation of a combined comorbidity index. Charlson M, Szatrowski TP, Peterson J, Gold J, J Clin Epidemiol 1994 47 1245 1251 10.1016/0895-4356(94) 90129-5 7722560
18. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA, Am J Respir Crit Care Med 1998 157 1418 1422 10.1164/ajrccm.157.5.9709032 9603117
19. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R, Thorax 2004 59 387 395 10.1136/thx.2003.008730 15115864
20. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM, Am J Respir Crit Care Med 2008 178 332 338 10.1164/rccm.200712-1869OC 18511702
21. Patient related factors in frequent readmissions: the influence of condition, access to services and patient choice. Kirby SE, Dennis SM, Jayasinghe UW, Harris MF, BMC Health Serv Res 2010 10 216 10.1186/1472-6963-10- 216 20663141
22. Airway and systemic inflammation and decline in lung function in patients with COPD. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA, Chest 2005 128 1995 2004 10.1378/chest.128.4. 1995 16236847
23. Risk indexes for exacerbations and hospitalizations due to COPD. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, Krumpe P, Pieper K, Kesten S, Chest 2007 131 20 28 10.1378/chest.06-1316 17218552
24. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Soler JJ, Sanchez L, Roman P, Martinez MA, Perpina M, Respir Med 2004 98 318 329 10.1016/j.rmed.2003.04.001 15072172